AIMC Topic: Fluorescein Angiography

Clear Filters Showing 1 to 10 of 144 articles

Updates on novel and traditional OCT and OCTA biomarkers in nAMD.

Eye (London, England)
Predictivity of optical coherence tomography (OCT) examination for the development of neovascular age-related macular degeneration (nAMD) was demonstrated to be superior compared to other methods, suggesting it as an elective method for screening pur...

D-GET: Group-Enhanced Transformer for Diabetic Retinopathy Severity Classification in Fundus Fluorescein Angiography.

Journal of medical systems
Early detection of Diabetic Retinopathy (DR) is vital for preserving vision and preventing deterioration of eyesight. Fundus Fluorescein Angiography (FFA), recognized as the gold standard for diagnosing DR, effectively reveals abnormalities in retina...

Artificial intelligence and different image modalities in uveal melanoma diagnosis and prognosis: A narrative review.

Photodiagnosis and photodynamic therapy
BACKGROUND: The most widespread primary intraocular tumor in adults is called uveal melanoma (UM), if detected early enough, it can be curable. Various methods are available to treat UM, but the most commonly used and effective approach is plaque rad...

Classification of fundus autofluorescence images based on macular function in retinitis pigmentosa using convolutional neural networks.

Japanese journal of ophthalmology
PURPOSE: To determine whether convolutional neural networks (CNN) can classify the severity of central vision loss using fundus autofluorescence (FAF) images and color fundus images of retinitis pigmentosa (RP), and to evaluate the utility of those i...

A Novel Management Challenge in Age-Related Macular Degeneration: Artificial Intelligence and Expert Prediction of Geographic Atrophy.

Ophthalmology. Retina
PURPOSE: The progression of geographic atrophy (GA) secondary to age-related macular degeneration is highly variable among individuals. Prediction of the progression is critical to identify patients who will benefit most from the first treatments cur...

AI in the clinical management of GA: A novel therapeutic universe requires novel tools.

Progress in retinal and eye research
Regulatory approval of the first two therapeutic substances for the management of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) is a major breakthrough following failure of numerous previous trials. However, in the absen...

Artificial intelligence for geographic atrophy: pearls and pitfalls.

Current opinion in ophthalmology
PURPOSE OF REVIEW: This review aims to address the recent advances of artificial intelligence (AI) in the context of clinical management of geographic atrophy (GA), a vision-impairing late-stage manifestation of age-related macular degeneration (AMD)...